Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Systemic Juvenile Idiopathic Arthritis
NCT03000439Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2018
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of tofacitinib in systemic juvenile idiopathic arthritis (SJIA), sponsored by Pfizer. Started May 2018; status: completed.
02
Drugs
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT03000439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000439.